Bruker/$BRKR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bruker
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Ticker
$BRKR
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
11,396
ISIN
US1167941087
Website
Bruker Metrics
BasicAdvanced
$6.6B
83.02
$0.52
1.18
$0.20
0.46%
Price and volume
Market cap
$6.6B
Beta
1.18
52-week high
$70.58
52-week low
$34.10
Average daily volume
2.3M
Dividend rate
$0.20
Financial strength
Current ratio
1.57
Quick ratio
0.665
Long term debt to equity
112.149
Total debt to equity
114.185
Dividend payout ratio (TTM)
38.44%
Interest coverage (TTM)
7.13%
Profitability
EBITDA (TTM)
607.4
Gross margin (TTM)
49.90%
Net profit margin (TTM)
2.31%
Operating margin (TTM)
11.58%
Effective tax rate (TTM)
50.53%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
4.88%
Return on equity (TTM)
4.76%
Valuation
Price to earnings (TTM)
83.021
Price to revenue (TTM)
1.905
Price to book
3.6
Price to tangible book (TTM)
-10.7
Price to free cash flow (TTM)
37.59
Free cash flow yield (TTM)
2.66%
Free cash flow per share (TTM)
115.94%
Dividend yield (TTM)
0.46%
Forward dividend yield
0.46%
Growth
Revenue change (TTM)
14.84%
Earnings per share change (TTM)
-80.80%
3-year revenue growth (CAGR)
11.92%
10-year revenue growth (CAGR)
7.08%
3-year earnings per share growth (CAGR)
-34.30%
10-year earnings per share growth (CAGR)
5.08%
3-year dividend per share growth (CAGR)
5.57%
What the Analysts think about Bruker
Analyst ratings (Buy, Hold, Sell) for Bruker stock.
Bulls say / Bears say
Bruker's recent launch of the timsOmni™ mass spectrometer enhances its product portfolio, potentially driving revenue growth in the proteomics and biomolecular analysis markets. (stocktitan.net)
The acquisition of biocrates life sciences ag strengthens Bruker's position in mass spectrometry-based quantitative metabolomics, expanding its capabilities in the life sciences sector. (businesswire.com)
Analysts maintain a cautiously optimistic stance on Bruker with 7 buy ratings and 7 hold ratings, and importantly, no sell ratings. The average target price of $53.95 per share implies a potential upside of 29.06% from the current price of $41.80. (directorstalkinterviews.com)
Bruker's high P/E ratio of 81.65 suggests the stock is trading at a premium compared to the market average, which may deter value-focused investors. (marketbeat.com)
The company's reliance on a limited number of suppliers for critical components poses a risk of supply chain disruptions, potentially affecting production and profitability. (tipranks.com)
Bruker's operations are dependent upon a limited number of suppliers and contract manufacturers. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Bruker Financial Performance
Revenues and expenses
Bruker Earnings Performance
Company profitability
Bruker News
AllArticlesVideos
Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands
Business Wire·3 weeks ago
Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
Business Wire·1 month ago
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bruker stock?
Bruker (BRKR) has a market cap of $6.6B as of July 12, 2025.
What is the P/E ratio for Bruker stock?
The price to earnings (P/E) ratio for Bruker (BRKR) stock is 83.02 as of July 12, 2025.
Does Bruker stock pay dividends?
Yes, the Bruker (BRKR) stock pays dividends to shareholders. As of July 12, 2025, the dividend rate is $0.2 and the yield is 0.46%. Bruker has a payout ratio of 38.44% on a trailing twelve-month basis.
When is the next Bruker dividend payment date?
The next Bruker (BRKR) dividend payment date is unconfirmed.
What is the beta indicator for Bruker?
Bruker (BRKR) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.